Company intelligence / Profile preview

Photon Biosciences

Spokane Valley, Washington, United Statesphotonbiosciences.com ↗

Ownership: Private
Employees: ~7
Development stage: Commercial

Overview

Photon Biosciences has developed a proprietary ultrasensitive detection platform based on genetically expressible luminescent bionanoparticles. Their lead programs include multiplexed point-of-care diagnostic tests for heart failure and blood platelet contamination. The company’s cardiac marker test aims to provide rapid, sensitive, multiplexed results suitable for at-home use or emergency settings. As of mid–2020s, their products are pre-commercial and undergoing further development toward regulatory approval.

Therapeutic areas: OtherCardiovascularHematology
Modalities: ProteinRecombinant proteinDeviceSmall molecule
Industry: Protein Biomarker Diagnostics

Partnerships

Washington State Universitycommercial and government entities (unnamed)

Beyond the preview

Go deeper on Photon Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Photon Biosciences.

Explore the full profile